<code id='DB005950AD'></code><style id='DB005950AD'></style>
      • <acronym id='DB005950AD'></acronym>
      <center id='DB005950AD'><center id='DB005950AD'><tfoot id='DB005950AD'></tfoot></center><abbr id='DB005950AD'><dir id='DB005950AD'><tfoot id='DB005950AD'></tfoot><noframes id='DB005950AD'>
      • <optgroup id='DB005950AD'><strike id='DB005950AD'><sup id='DB005950AD'></sup></strike><code id='DB005950AD'></code></optgroup>
        5. <b id='DB005950AD'><label id='DB005950AD'><select id='DB005950AD'><dt id='DB005950AD'><span id='DB005950AD'></span></dt></select></label></b><u id='DB005950AD'></u>
          <i id='DB005950AD'><strike id='DB005950AD'><tt id='DB005950AD'><pre id='DB005950AD'></pre></tt></strike></i>
           


   

   

   
   
   
   
   
   
   
   
   
   
   
   
   

   
   
   
   
   
   
   
  
           
  
           
  
           
   
           
    
           
     
           
      
           
       
      
           
      
           
       
           
        
           
         
           
           
          
           
         
           
         
           
           
          
           
         
           
          
        
           
       
           
       
           
        
           
        
           
        
           
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
       
           
       
           
        
           
        
          
          00:00 
        
           
       
           
       
           
      
           
      
           
        
        
        
       
           
        00:00 
         
        00:00 
        LIVE 
       
           
        
       
           
        
           
        
           
        
           
        
           
       
           
       
           
       
           
        
        
        
        
        
        
        
        
        
      
           
       
    
    
      
           
       
           
      
           
     
           
     
           
       
     
           
     
           
      
           
      
           
      
           
      
           
       
           
      
           
      
           
      
           
       
           
       
          
         buffering 
       
           
      
           
      
           
       
           
        
           
        
          
          Replay 
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
        
           
        
           
        
           
       
           
      
           
      
           
      
           
      
           
      
           
       
           
      
           
     
           
     
           
      
           
     
           
     
           
      
           
       
           
        
           
       
           
       
           
        
          
          LIVE 
        
           
        00:00 
         /  
        00:00 
       
           
       
           
        
           
        
           
        
           
         
           
         
           
         
           
         
           
         
           
         
           
        
           
        
           
        
           
       
           
       
           
        
           
        
          
          LIVE 
        
           
       
           
       
           
        
           
        
          
          CC 
        
           
       
           
       
           
        
           
       
           
       
           
       
           
        
           
        
           
         
           
        
           
       
           
       
           
        
           
       
           
      
           
      
           
       
           
        
           
        
           
         
           
         
           
         
           
          
           
          
           
          
           
         
           
        
           
       
           
      
           
      
           
       
           
     
       
           
    
       
           
       
    
  
       
           
   
       
           
       
       
           
      
           
      
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       Opacity : 
        
      
           
     
           
     
           
     
           
      
           
  
     
           
    
           
    
           
    
           
     
          
       Share: 
     
           
      
     
           
      
      Copy 
     
           
      
    
           
    
          
      Close 
      
    
           
    
           
      
    
           
    
           
   
           
  
           
  
           
    
    
    
   
           
   
           
 
    
   
           
   
           
   
           
    
           
     
           
      
           
       
           
        
           
          
          
         
          
          hotspot 

          
          
            
          
          

           
           
        
           
       
           
      
           
     
           
    
           
    
           
     
           
      
           
      
           

                       
          Wikipedia  
          
                                   
                 
                                      author：fashion   
                                        
                                      
                                      -
 
browse：276
                                  
                                    
          
                                    
            
          
 
          Adam's take main illustration
          Molly Ferguson/STAT
          The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.
          Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.
          advertisement
          The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
           
 
 
          

                              
          
                                 Previous article：

                                
                                          Alkermes shareholders re
                                
                            
          Next article：  
                                      
                                          First medicine developed to treat MASH expected to be approved soon
                                                                    
          

      
           
      
           
        
           
                                               
        
           entertainment 
           
                   
      
           
  
  
          
    
          
        
          
            
          
                                                     
                
          knowledge
          
                            
          
        
          
        
    
          

          

    

      
           
     
           


   
    
           
   
           
  
 

  
           
    
           
           
           
            
            Back To Top 
           
           
           
           

            
           
                                                                    
                 
          hotspot
           
                                      
            
           
          
           
                                                          
             
          hotspot
           
                             
            
           
            
           

                                                         
             
          hotspot
           
               
              
            
           
            
           
                                                         
             
          focus
           
                             
      
           
 
     
           
     
           
      
          
              AdobeMedicareannouncedonSaturdaythatitwillmakeadvancepaymentsavailabletophysiciangroups,hospitals,an
             
           
      
          
        © 2013-2023.Company name All rights reserved.Site Map 
         WSS-More Templates  
             Guangdong ICP92751name